Endokrinologie Cerny Most sro

The trials here

What the 3 trials at this site are about, from their registry records.

Conditions

• Obesity3 trials
• Type 2 diabetes2 trials

Phase

• Phase 33 trials

Status

• Active, not recruiting3 trials

Lead sponsor

• Amgen3 trials

Running trials

• Active, not recruiting

  Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

  NCT07037433· Phase 3· Amgen· Source

• Active, not recruiting

  Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

  NCT06858878· Phase 3· Amgen· Source

• Active, not recruiting

  Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

  NCT06858839· Phase 3· Amgen· Source